The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review

Página do item simplificado
dc.creatorLuciana Mendes Araújo Borém
dc.creatorJoão Felício Rodrigues Neto
dc.creatorIgor Viana Brandi
dc.creatorDeborah de Farias Lelis
dc.creatorSergio Henrique Sousa Santos
dc.date.accessioned2022-08-22T13:05:58Z
dc.date.accessioned2025-09-09T00:43:24Z
dc.date.available2022-08-22T13:05:58Z
dc.date.issued2018-04-10
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.identifier.doi10.1038/s41440-018-0040-6
dc.identifier.issn1348-4214
dc.identifier.urihttps://hdl.handle.net/1843/44430
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofHypertension Research
dc.rightsAcesso Aberto
dc.subjectFígado - Doenças
dc.subjectAngiotensina
dc.subjectSistema renina-angiotensina
dc.titleThe role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review
dc.typeArtigo de periódico
local.citation.epage405
local.citation.spage394
local.citation.volume41
local.description.resumoNon-alcoholic fatty liver disease (NAFLD) is currently considered an important component of metabolic syndrome (MetS). The spectrum of NAFLD includes conditions that range from simple hepatic steatosis to non-alcoholic steatohepatitis. NAFLD is correlated with liver-related death and is predicted to be the most frequent indication for liver transplantation by 2030. Insulin resistance is directly correlated to the central mechanisms of hepatic steatosis in NAFLD patients, which is strongly correlated to the imbalance of the renin–angiotensin system, that is involved in lipid and glucose metabolism. Among the emerging treatment approaches for NAFLD is the anti-hypertensive agent telmisartan, which has positive effects on liver, lipid, and glucose metabolism, especially through its action on the renin–angiotensin system, by blocking the ACE/AngII/AT1 axis and increasing ACE2/Ang(1–7)/Mas axis activation. However, treatment with this drug is only recommended for patients with an established indication for anti-hypertensive therapy. Thus, there is an increased need for large randomized controlled trials with the aim of elucidating the effects of telmisartan on liver disease, especially NAFLD. From this perspective, the present review aims to provide a brief examination of the pathogenesis of NAFLD/NASH and the role of telmisartan on preventing liver disorders and thus to improve the discussion on potential therapies.
local.publisher.countryBrasil
local.publisher.departmentICA - INSTITUTO DE CIÊNCIAS AGRÁRIAS
local.publisher.initialsUFMG
local.url.externahttps://www.nature.com/articles/s41440-018-0040-6

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease.pdf
Tamanho:
827.18 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG